Aurora Cannabis Inc. (ACB) – What Are Researchers Thinking About This Stock?

Aurora Cannabis Inc. (NASDAQ:ACB) has been given an average rating of “Reduce” by the five brokerages that are presently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and one has issued a buy recommendation on the company.

Several equities analysts have recently weighed in on ACB shares. Weiss Ratings upgraded shares of Aurora Cannabis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 2nd. Zacks Research cut Aurora Cannabis from a “strong-buy” rating to a “hold” rating in a report on Monday, October 5th. Wall Street Zen raised Aurora Cannabis from a “sell” rating to a “hold” rating in a research note on Sunday, September 13th. TD Securities downgraded Aurora Cannabis from a “strong-buy” rating to a “strong sell” rating in a research note on Tuesday. Finally, BMO Capital Markets upgraded Aurora Cannabis to a “hold” rating in a research note on Wednesday, August 5th.

Aurora Cannabis Price Performance

Shares of Aurora Cannabis stock opened at $5.24 on Thursday. Aurora Cannabis has a 52 week low of $2.56 and a 52 week high of $6.36. The company has a quick ratio of 2.80, a current ratio of 5.36 and a debt-to-equity ratio of 0.03. The business has a 50 day moving average of $4.10 and a 200 day moving average of $3.56. The company has a market cap of $344.39 million, a PE ratio of -3.72 and a beta of 0.65.

Aurora Cannabis (NASDAQ:ACB) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.13) by $0.17. The business had revenue of $47.62 million for the quarter, compared to analyst estimates of $47.45 million. Aurora Cannabis had a negative net margin of 32.26% and a positive return on equity of 4.37%. As a group, equities research analysts forecast that Aurora Cannabis will post -0.07 earnings per share for the current year.

Institutional Trading of Aurora Cannabis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tidal Investments LLC increased its holdings in Aurora Cannabis by 1.2% in the 2nd quarter. Tidal Investments LLC now owns 1,264,494 shares of the company’s stock worth $3,528,000 after buying an additional 14,827 shares during the period. Baader Bank Aktiengesellschaft raised its holdings in shares of Aurora Cannabis by 37.3% during the first quarter. Baader Bank Aktiengesellschaft now owns 33,060 shares of the company’s stock worth $108,000 after purchasing an additional 8,990 shares during the last quarter. State of Wyoming lifted its position in Aurora Cannabis by 26.2% during the third quarter. State of Wyoming now owns 25,303 shares of the company’s stock valued at $99,000 after purchasing an additional 5,250 shares during the period. Finally, Two Sigma Securities LLC purchased a new position in shares of Aurora Cannabis during the 2nd quarter valued at about $36,000. Institutional investors and hedge funds own 47.63% of the company’s stock.

Aurora Cannabis Company Profile

Aurora Cannabis Inc is a Canadian cannabis company headquartered in Edmonton, Alberta. Founded in 2013, the company develops, produces, distributes and sells cannabis and cannabis-derived products for medical and adult-use markets. Its shares trade on the Toronto Stock Exchange and the Nasdaq under the symbol ACB.

Aurora’s product portfolio includes dried cannabis flower, pre-rolls, cannabis oils, softgels, vapes and other cannabis extracts. The company markets products through brands such as Aurora, San Rafael ’71, Daily Special and CanniMed, with offerings varying by market and applicable regulations.

The company serves Canada’s regulated adult-use and medical cannabis markets and has expanded its medical cannabis business internationally.